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Aim: Intravenous lipid emulsion (ILE) can become a risk factor for intestinal failure associated liver disease
(IFALD). Many ILEs are commercially available, however, a direct comparison of their impact on liver has, to
our knowledge, never been performed. The aim of the study was to analyse that clinical problem during long
term parenteral nutrition (PN).
Methods: A randomized, controlled clinical trial was performed at the Intestinal Failure Center in Skawina,
Poland. Sixty-seven patients (37 F, 30M, mean age 53.9 years) enrolled in home parenteral nutrition (HPN)
due to stable chronic intestinal failure (CIF) were randomized to receive one the following for 12 months:
long-chain triglycerides (LCT), medium/long-chain triglycerides, olive oil/LCT (OO/LCT) and a mix of LCT/
MCT/OO/fish oil. Clinical evaluation and biochemical tests (total bilirubin, SGOT, SGTP, GGPT, alkaline phos-
phatase) were performed at enrolment and after 6 and 12 months.
Results: the most common reason for intestinal failure (IF) was short bowel due to mesenteric ischaemia, fol-
lowed by Crohn's disease, surgical complications and radiation enteritis. PN stabilized liver parameters in all
patients. No essential fatty acids deficiency was diagnosed. All four ILEs demonstrated comparable influence
on liver in all study periods. The only exception was the decrease in total bilirubin concentration after 12
months (28.1§25.3 vs 11.1§4.5, p = 0.0023) and GGTP (222.5§205.8 vs 146.6§197.7, p = 0.0079) when
OO/LCT was in use.
Conclusions: All four ILEs tested may be safe even during long-term parenteral nutrition. OO/LCT may be
more effective than the others, but more studies in the field are needed.
© 2018 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)Keywords:
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Intravenous lipid emulsions (ILEs), which are essential compo-
nents of parenteral nutrition (PN), are a good source of energy as
well as essential fatty acids (FAs) [15]. The first ILEs were based on
cotton seed oil or soybean oil (i.e., long-chained triacylglycerols
[LCTs]) [310] and were useful in metabolically stable patients butdeleterious in septic and unstable patients and perhaps also in those
who receive long-term nutrition support. Hence, less proinflamma-
tory and immunosuppressive ILEs were developed. These newer
ILEs included mixtures of medium-chain triacylglycerols (MCTs) and
LCTs, olive oil and LCT (OO/LCT; ClinOleic, Baxter Healthcare), and
MCT, LCT, OO, and fish oil (SMOFlipid, Fresenius Kabi) [3,711].
In general, there appear to be few differences in patient outcomes
when using these different ILEs. A pure fish-oil ILE is also available but
although this has been shown to be effective in the intensive care unit
after surgery and in patients with liver failure [11], there are concerns
that pure fish oil may not supply sufficient essential FAs. On the other
hand, a recent study by Anez-Bustillos et al. [12] proved otherwise;
hence, patients who do not receive ILEs other than omega-3-polyun-
saturated FAs (PUFAs) may not develop essential FAs deficiency.
Table 1
General characteristics and nutritional parameters by group
Lipofundin MCT/LCT ClinOleic Smoflipid Intralipid P value
General description
Number of patients, n 18 17 16 14 —
Female, n (%) 10 (55.5%) 10 (58.8%) 8 (50%) 9 (56.25%) 0.6585*
Male, n (%) 8 (44.5%) 7 (41.2%) 8 (50%) 5 (43.75%)
Mean age, y§ SD 56.3§15.4 54.8§12.9 47.8§12.5 59.6§17.6 0.1190y
Mean BMI at baseline, kg/m2§ SD 19.5§4.2 18.9§2.9 18.5§4.3 22.2§6.5 0.1865y
Mean BMI at 3mo, kg/m2§ SD 21.5§3.9 19.9§2.8 20.5§4.1 22.0§4.5 0.4913y
Mean BMI at 12 mo, kg/m2§ SD 21.4§3.3 22.3§2.1 20.2§4.5 24.0§3.9 0.0264yz
Nutritional support
Length of PN before admission (d) 23§3.5 22§4.0 25§1.5 25§2.0 0.366
Mean lipid, g/kg body weight/d§ SD 0.7§0.2 0.6§0.4 0.7§0.2 0.7§0.2 0.3412y
Mean energy, kcal/kg/d§ SD 20.0§4.4 20.8§5.8 23.1§6.1 18.2§5.4 0.0627y
Mean nitrogen, g/kg/d§ SD 0.15§0.2 0.16§0.1 0.15§0.1 0.16§0.2 0.0333yx
Mean volume administered, mL/d§ SD 1332.5§390.9 1428.1§233.1 1448.2§896.7 1446.8§203.2 0.0036y
Mean number of PN bags used per week, § SD 6.1§1.0 6.1§0.9 6.2§1.0 5.6§0.7 0.0013y
Cather-related bloodstream infections per 1000 catheter d 0.55 0.7 0.35 0.6 0.667
BMI, body mass index; LCT, long-chain triacylglycerols; MCT, medium-chain triacylglycerols; PN, parenteral nutrition; SD, standard deviation.
*x2 test.
yAnalysis of variance.
zSmoflipid and Intralipid groups are different.
xClinOleic and Smoflipid groups are different.
Table 2
Causes of intestinal failure by group
Cause of intestinal
failure
Lipofundin
MCT/LCT
(n =18)
ClinOleic
(n = 17)
Smoflipid
(n =16)
Intralipid
(n = 14)
Vascular 7 8 7 6
46 S. Klek et al. / Nutrition 5556 (2018) 4550Some patients such as those who are critically ill, have chronic
intestinal failure (CIF), and receive home parenteral nutrition (HPN)
are particularly exposed to intestinal failure-associated liver disease
(IFALD) [1319]. IFALD is one of the most dangerous complications of
HPN and is potentially life threatening [13,14]. PN, intestinal failure,
and inflammation are etiological factors that influence the risk of
developing IFALD [19]. The amount and type of ILE that is used in PN
and the possible excess of energy intake are among the possible major
causes of IFALD [13]. ILEs at a dose of >1g fat/kg body weight/d and
omega-6-PUFAs as a sole source of lipids are known to play a role in
the etiology of IFALD [11]. If decreasing the amount of energy intake
and/or the excess of lipids is not effective enough, the antiinflamma-
tory properties of the second or third generation ILEs may be the only
method to improve the liver function. Themost significant clinical out-
come has been observed with omega-3-PUFAs as the sole ILE or in
combination with other ILEs. The clinical gain is the most spectacular
in the pediatric population [17]. Some authors observed an improve-
ment in the liver function of adults as well; however, this was obvious
only for omega-3-PUFAs and the impact of other ILEs remains
unknown.
Moreover, no study has directly compared the impact of all com-
mercially available ILEs on the liver in adults who receive long-term
HPN. Therefore, the aim of this study was to compare all four ILEs
with regard to impact on the liver by assessing the clinical status of
patients and liver test results after 12mo. Total bilirubin and liver
tests along with clinical status were selected to describe the liver
function because their elevation and particularly the progressive
one may indicate an emerging risk of IFALD. The primary hypothesis
was that the second generation of ILEs will improve the liver test
results and decrease total bilirubin during HPN compared with LCTs.Crohn's disease 3 3 4 2
Surgical 2 2 2 2
Radiation enteritis 2 1 — 1
GI fistula (Crohn's disease
excluded)
1 — 1 1
Malabsorption 1 1 — —
Motility disorders 1 — — 1
Benign GI obstruction 1 — — —
Trauma — 1 1 —
Necrotizing enterocolitis — — 1 —
Other — 1 — 1
GI, gastrointestinal; LCT, long-chain triacylglycerols; MCT, medium-chain
triacylglycerols.Methods
A randomized, controlled, clinical study of four parallel groups was performed
at the Intestinal Failure Center of the Stanley Dudricks' Memorial Hospital in Ska-
wina, Poland between January 1, 2010 and December 31, 2015. A total of 88
patients (48 male and 40 female patients; mean age: 54.5 y) who were admitted to
start HPN due to stable CIF were randomly assigned during the recruitment period
(January 2010March 2014) to receive PN with one the following lipid emulsions:
LCTs (LCT group; Intralipid, Fresenius Kabi, Germany); MCTs/LCTs 50:50 (MCT/LCT
group; Lipofundin, B Braun Germany); OO/LCTs 80:20 (OO group; ClinOleic, Baxter
Healthcare); and MCTs/LCTs/OO/fish oil (SMOF group; SMOFLipid, Fresenius Kabi,Germany). The solutions were mixed with other macro- and micronutrients at the
compounding unit of the Skawina Hospital pharmacy.
Assignment to the treatment groups was performed after assessment and
check of the inclusion and exclusion criteria. The randomization and blinding were
performed by the chief of the hospital pharmacy. The study treatment was blinded
for the physician and patient. Consecutive patients were randomly assigned to one
of the four treatment groups using sequentially numbered, sealed, and opaque
envelopes. Patients were matched on the basis of age, sex, body mass index, type
of nutrition, and diagnosis.
Patients were referred to the intestinal failure center from other hospitals
around the country. All patients received all-in-one PN with ILE before inclusion in
the study; however, detailed data on the type of emulsion were unavailable
because hospitals are not obliged to report these data at the time of discharge.
Detailed characteristics of the patients are presented in Tables 1 and 2.
Intervention
The test emulsion was added to the regular PN admixture, which was used to
feed patients at home. The study lasted 12mo. The treatment period was defined
as the time from the first administration of the study drug until the final infusion
and the follow-up period included 4wk after the last administration of the tested
emulsion drug.
The study was terminated if the laboratory test results showed a serum triacyl-
glycerol concentration >3mmol/L (>262.5mg/dL), an intolerable or serious
adverse event was observed, or a failure of therapeutic safety or tolerability caused
an unacceptable risk/benefit ratio.
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The inclusion criteria were 18 y of age, CIF while on PN including lipids, met-
abolic stability (i.e., absence of pathologic laboratory testing that resulted in a
change of PN regime for at least 1mo), and ability to tolerate up to 1.0 g lipids/kg
body weight per day as a part of PN. The exclusion criteria were preexisting liver
dysfunction (i.e., elevated levels of serum glutamic oxaloacetic transaminase,
serum glutamate pyruvate transaminase, total bilirubin, gamma-glutamyl trans-
peptidase [GGTP], and alkaline phosphatase >3£normal value), history of cancer
and anticancer treatment within the last 5 y, severe hyperlipidemia, severe coagul-
opathy, severe renal insufficiency, acute thromboembolic events, positive test for
HIV, Hepatitis B or C (from medical history), known or suspected drug or alcohol
abuse, and participation in another interventional clinical trial in parallel or within
3mo before the start of this clinical trial. Women with childbearing potential (i.e.,
female patients who are not chemically or surgically sterile or not postmeno-
pausal), of childbearing potential who tested positive on a standard pregnancy test
(e.g., urine dipstick), and/or those who are lactating were also excluded from the
study.
Clinical management
ILEs were infused via a central venous catheter as part of all-in-one solutions
along with amino-acids, glucose, electrolytes, vitamins, and trace elements. For
each patient, the required nutritional supply was calculated per day. The lipid
delivery rate was established to stay between 0.6 and 0.8 g/kg/d. All patients were
allowed to consume food orally. The oral provision of nutrients did not exceed 10%
of the entire energy and protein intake, which was assessed by a dietitian.
Biochemistry, hematologic, coagulation, and inflammatory parameters as well
as vital signs were determined. All adverse events were documented and evalu-
ated. The laboratory variables included for biochemistry were triacylglycerols,
total cholesterol, alkaline phosphatase, serum glutamic oxaloacetic transaminase,
GGTP, serum glutamate pyruvate transaminase, sodium, potassium, chloride, mag-
nesium, calcium, phosphate, total bilirubin, creatinine, urea, glucose, albumin, and
total protein. Hematologic laboratory variables were leucocytes, platelets, erythro-
cytes, hemoglobin, and hematocrit. Coagulation was determined using the interna-
tional normalized ratio.
Clinical variables
The clinical variables for the study were incidence of cholestasis (defined as
either conjugated bilirubin >3-fold upper limit of normal and either GGTP or alka-
line phosphatase >3-fold upper limit of normal, or conjugated bilirubin alone
>2mg/dL without an explanation for another etiology such as viral hepatitis),
adverse events, and vital signs (blood pressure [mmHg], heart rate [beats/min],
and body temperature [°C]). The laboratory safety variables and vital signs were
recorded every 3mo, 12h after completion of an infusion and before the start of
the next infusion.
Adverse events were registered during the entire study period and during the
4wk of follow-up time. An adverse event was defined as any untoward medical
occurrence in a patient that did not necessarily have a causal relationship with the
treatment. A serious adverse event was any untoward medical occurrence that at
any dose resulted in death, was life threatening (“life threatening” in the definition
of “serious” referred to an event in which the patient was at risk of death at the
time of the event but not an event that hypothetically might have caused death if
it were more severe), required inpatient hospitalization or the prolongation of an
existing hospitalization, resulted in persistent or significant disability/incapacity,
or was a congenital anomaly/birth defect.
The intensity of all adverse events was rated in accordance with the Common
Terminology Criteria for Adverse Events version 3.0. Each adverse event was classi-
fied in one of the five categories and represented the maximum intensity that was
reported during the evaluation period in question. The classifications were grade 1
mild, grade 2 moderate, grade 3 severe, grade 4 life threatening or disabling, and
grade 5 death-related adverse event.
Ethics and consent
The ethics committee of the Jagiellonian University Medical School approved
the study [KBET/39/L/2010]. Patients were approached and enrolled by one of two
investigators (SK, KSz). Informed written consent was obtained from each partici-
pant before enrollment. The study was carried out in accordance with the interna-
tional ethical recommendations of the Helsinki Declaration and registered under
number NCT03044639 at ClinicalTrials.gov.
Statistical analysis and sample size calculation
All data were analyzed with Statsoft STATISTICA version 12. The results are
presented as either mean§ standard deviation (SD) or median as appropriate. The
study of the categorical variables used the x2 test of independence. The Shapiro-Wilk test was used to check for normal distribution of data. For non-normally dis-
tributed quantitative variables, the Kruskal Wallis test was used and for normally
distributes variables, when the remaining test assumptions were met, an analysis
of variance was conducted. Post hoc analyses included the Tukey and Dunn tests.
The results were considered statistically significant when the P value was<0.05.
The decrease/increase of the liver parameters after 12mo was assumed to be
approximately 100% and a dropoff rate of 20% was anticipated. To detect an
increase or decrease in the concentration of liver parameters by 100% due to lipid
emulsion, approximately 15 patients were allocated to each of the two compared
arms (a = 0.05 two-sided; power = 0.80). The sample size was calculated using
SamplePower 2 (SPSS Inc, Chicago, IL).Results
Eighty-eight patients were randomized but only 65 patients
(37 female and 28 male patients; mean age: 53.9 y) completed the
12-mo study period and were eligible for the analysis per the
protocol (Fig. 1).
Relatively many patients were lost to follow-up (n =16) due to
transfer to another HPN center (n = 11), elective surgery for gastro-
intestinal fistula (n =3), and weaning off/ reduction of HPN due to
improved function of the gastrointestinal tract (n =3). There were
no significant differences among the study groups with regard to
sex, age, body mass index, underlying disease, and intake of energy,
proteins and lipids (Tables 1 and 2).
The liver test results are presented in Table 3. The results nor-
malized with time in all groups to the extent that after the 12-mo
period, no statistically significant differences were observed
between the groups (Table 3). Thus, the primary hypothesis of the
study was not supported because none of the alternative ILEs was
more effective than LCTs (Intralipid).
No serious adverse events were observed during the study
period and no patients were prematurely terminated from the
study due to an adverse event or serious adverse event. No signs of
essential FA deficiency were diagnosed.
Oral intake was analyzed in all patient groups and changed/
increased with time; however, the time differences among the
groups were not significant. The omega-9 FA-rich ILE based on OO
(ClinOleic); however, reduced the bilirubin concentration
(28.1§25.3mmol/L at the beginning versus 11.1§4.5mmol/L at
the end; P= 0.0023) and GGTP (222.5§205.8 IU/L versus
146.6§197.7 IU/L; P =0.0079). No other lipid emulsion exerted
such an effect but this group started from the higher values at the
beginning of the study. Nonetheless, this was the only group to
demonstrate the trend between the 6th and 12th month.Discussion
ILE is an indispensable constituent of PN because it is a very
good source of energy and essential FAs [15]. The oldest emulsion
is LCT, which is soybean-derived and has been used for decades.
LCT has been proven to be safe and well tolerated but potentially
harmful because of the overzealous production of inflammatory
mediators during long-term PN. New-generation ILEs such as
MCTs, OO, and fish oil have been proven to be safer and have been
gaining more attention. Also, these new ILEs have proven their
clinical effectiveness in some patient groups. For example, the use
of MCT/LCT emulsion helped to reduce the length of mechanical
ventilation in patients in intensive care units, improved the condi-
tion of patients with chronic obstructive pulmonary disease, and
improved albumin synthesis [1518]. In surgical patients, a reduc-
tion of postoperative complications was observed even with the
reduction of morbidity after hemihepatectomy [19,20].
OO has been observed to decrease oxidation and improve lym-
phocyte function [20]. Sala-Vila et al. [21] have summarized the
Table 3
Liver function markers by group
Lipofundin MCT/LCT ClinOleic Smoflipid Intralipid P value
Day 0
Median SGPT (UI/L, IQR) 26.0 (1538) 38.5 (26106) 33.5 (25.541.5) 34.0 (1874) 0.0144*,y
Normal range:<40 IU/L
Median SGOT (UI/L, IQR) 23.3 (15.133) 35 (2768) 22 (16.529.5) 28 (19.938) 0.0109*
Normal range:<40 IU/L
Median GGTP (UI/L, IQR) 68 (28112.3) 165 (77202) 66 (3290) 60 (40174) 0.0220*,y
Normal range:<40 IU/L
Median alkaline phosphatase (UI/L; IQR) 128.5 (92219.3) 175.5 (102330) 163 (112324) 134.5 (89219) 0.5380*
Normal value:<270 IU/L
Median bilirubin (mmol/L, IQR) 9.4 (5.916.0) 18.0 (11.633.7) 9.4 (7.612.3) 9.4 (5.918.5) 0.0045*,y
Normal range, 3.4220.6mmol/L
Median oral energy intake (kcal/d) 534.5 (150760) 605.1 (95810) 555.5 (205790) 608.2 (170780) >0.05
After 6mo of HPN
Median SGPT (IQR) 25 (1847) 40 (22.559.5) 37.6 (21.556.5) 28 (2048) 0.1679*
Mean SGOT§ SD 28.1§17.4 33.0§13.6 31.7§15.5 30.0§14.7 0.1709z
Median GGTP (IQR) 44.3 (25105.9) 83.8 (27.5246.5) 74 (27.594.6) 47 (2581) 0.3416*
Mean fatty acids§ SD 194.0§159.8 231.8§192.0 203.1§128.4 192.2§100.5 0.7817z
Mean bilirubin§ SD 12.3§9.8 13.1§6.8 18.4§16.7 20.0§34.6 0.0857z
Median oral energy intake (kcal/d) 1380.4 (4002200) 1290 (5502350) 1352.5 (5002350) 1432.5 (4902100) >0.05
After 12mo of HPN
Mean SGPT§ SD (U/L) 36.1§29.2 53.8§54.7 47.3§48.7 38.0§29.5 0.8779z
Mean SGOT§ SD (U/L) 29.6§23.3 50.1§56.0 42.7§45.7 31.1§23.0 0.5749z
Median GGTP (U/L; IQR) 45.5 (2380.5) 29 (1991.8) 78 (27.580) 65 (32.6103) 0.3616*
Mean alkaline phosphatase§ SD (U/L) 214.3§213.7 188.5§124.5 280.2§427.5 233.4§318.6 0.9565z
Mean bilirubin§ SDmmol/L 14.0§10.2 11.1§4.5 14.0§10.9 16.8§13.5 0.8466z
Median oral energy intake (kcal/d) 1480.5 (510.12405) 1510.7 (5252240) 1520.7 (6702350) 1476.5 (5102211) >0.05
GGTP, gamma-glutamyl transpeptidase; HPN, home parenteral nutrition; IQR, interquartile range; LCT, long-chain triacylglycerols; MCT, medium-chain triacylglycerols;
SD, standard deviation; SGOT, serum glutamic oxaloacetic transaminase; SGPT, serum glutamate pyruvate transaminase.
*Kruskal-Wallis H test.
ySignificant difference between the Lipofundin and Clinoleic groups.
zAnalysis of variance.
Fig. 1. CONSORT diagram.
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well tolerated, and present advantages in the liver function of
patients with burns. Fish oil is a source of bioactive omega-3-PUFAs,
eicosapentaenoic, and docosahexaenoic, which are recognized to
reduce inflammation [4] and modify lipid metabolism, blood lipid
concentrations, coagulation, inflammation, and immune function
[10].
As mentioned previously, the PN regimen and particularly the
type of ILE can be the etiological factor in the development of IFALD
[19]. Therefore, the new ILEs should be beneficial in terms of hepa-
toprotection. Surprisingly, there has been a scarcity of valuable
research on ILEs and IFALD in adults and a direct comparison of
commercially available ILEs that are used for long-term PN has
never been performed.
To our knowledge, our study is the first to be performed for such
a long time period and prove that liver tests may normalize with
time regardless of ILE type. Therefore, it can be assumed that none
of the alternative ILEs was more effective than LCT (Intralipid),
which proves the point that it is the quality of PN that matters the
most. On the other hand, omega-9 FA-rich ILE that is based on OO
(ClinOleic) reduced the bilirubin concentration (28.1§25.3 at the
beginning versus 11.1§4.5 at the end; P=0.0023) as well as GGTP
(222.5§205.8 versus 146.6§197.7; P=0.0079). No other lipid
emulsion exerted such an effect. Therefore, we may speculate that
some ILEs may be more effective than others. The pure omega-3-
PUFA solution (Omegaven, Fresenius Kabi, Germany) was not
included in the study because the use of pure fish oil solutions as the
sole lipid source in PN may lead to essential FAs deficiency. In addi-
tion, to our knowledge, this is the first study to compare ILEs in
patients with CIF who are totally dependent on HPN. The other
strengths of the study include the long-time duration, a direct com-
parison of all four available ILEs, and the homogenous study group.
Nonetheless, the authors are aware of some limitations of the
study such as the relatively significant loss to follow-up, lack of
intent-to-treat (ITT) analysis or incomplete assessment of the labo-
ratory parameters (including C-reactive protein and conjugated bili-
rubin), and lack of precise data on the PN used in other hospitals in
terms of total energy provision and type of ILE used. These data
were unobtainable because discharge papers do not have to contain
that kind of data; hence, if the physician-in-charge did not provided
us with that information, it was impossible to obtain. The same
applies to the lack of length of PN in those units. The reason for the
lack of ITT analysis was the doubt whether ITT including all patients
(even those who received HPN for 1 to 2mo) would contribute to
the full picture of long-term PN and long-term use of ILEs.
Other available studies suffer from drawbacks as well. First, the
research is short-term and generally not longer than 4wk. Only
two trials lasted longer (but only up to 6mo), which disqualifies
them as CIF studies [7,2226]. Second, these studies were mostly
non-inferiority studies, which did not prove any advantage of the
newer emulsion over the traditional one [2225]. Finally, many of
the trials suffer from poor methodology (e.g., small groups and lack
of randomization) or are just case reports [2227].
Our results differ from those of the majority of available studies.
A new systematic review on non-alcoholic fatty liver disease
(NAFLD) showed that in 12 of 17 trials, a decrease in liver fat and/
or other markers of NAFLD after supplementation with omega-3
PUFAs was reported [28]. Those findings suggest a leading key role
for omega-3-PUFAs in the prevention of liver failure. However, not
all of the included results can be applied to IFALD because patients
with NAFLD do not suffer from intestinal failure and do not use PN.
Pediatric trials have suggested much promise from inclusion of
omega-3 PUFAs in PN and prevention or reversal of IFALD. de
Meijer et al. [29] and Vernick et al. [30] observed the positiveimpact of fish oil in liver disease in newborn infants. In our study,
fish oil-containing ILE did not demonstrate any favorable clinical
impact, which is consistent with the meta-analysis by Seide et al.
[31], who demonstrated a lack of sufficient high-quality data to
support the use of parenteral omega-3 PUFAs in children.
The impact of oral intake was analyzed in our patients' group.
However, we did not find any differences among the groups; hence,
we assumed that oral intake could not influence the outcomes.
The scale of positive impact of OO-based ILE in our study was
only partially surprising. Some authors observed a hepatoprotective
effect of OO in their studies but never in long-term observations
[3236]. Moreover, OO has been known for its resistance to oxida-
tive stress and the lowest proinflammatory effect, which has been
observed in both in vitro and in vivo studies [21,32,33]. OO is an
important component of the Mediterranean diet, which is consid-
ered the healthiest diet in the world. Nevertheless, one could have
expected an intravenous effect that was different from the oral one.Conclusions
In our opinion, the present study shows that if designed prop-
erly, PN is a safe therapy even in patients with CIF. This was proven
by the normalization of the liver test results in all patients after the
introduction of ILE as part of HPN. Moreover, all ILEs are safe and
effective with regard to the liver even during long-term PN. We
may hypothesize that OO-based ILE is more promising than other
ILEs during long-term PN; however, some limitations of our study
(e.g., highest initial total bilirubin concentration for that group)
clearly demonstrate the need for more studies.References
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